Curbstone Financial Management Corp Makes New $526,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Curbstone Financial Management Corp bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 8,240 shares of the biopharmaceutical company's stock, valued at approximately $526,000.

A number of other large investors have also recently bought and sold shares of HALO. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC boosted its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares in the last quarter. UMB Bank n.a. boosted its position in Halozyme Therapeutics by 267.4% in the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock worth $84,000 after purchasing an additional 960 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Down 1.0%

Halozyme Therapeutics stock traded down $0.56 during midday trading on Friday, reaching $53.98. 1,218,546 shares of the stock traded hands, compared to its average volume of 1,634,157. The company has a 50-day simple moving average of $57.34 and a two-hundred day simple moving average of $56.18. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The firm has a market cap of $6.65 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.79 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on HALO. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research report on Tuesday, May 13th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. Finally, Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.